Campbell Newman Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Campbell Newman Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-6,547	Closed	-$554K	–	125
2018 Q4	$554K	Buy	6,547 +2,525	+63%	+$269K	0.1%	90
2018 Q3	$689K	Sell	4,022 -2,095	-34%	-$316K	0.1%	87
2018 Q2	$791K	Buy	6,117 +263	+4%	+$29.3K	0.12%	71
2018 Q1	$603K	Buy	5,854 +252	+4%	+$24.9K	0.1%	88
2017 Q4	$479K	Buy	5,602 +1,021	+22%	+$88.5K	0.08%	96
2017 Q3	$389K	Buy	4,581 +583	+15%	+$46.2K	0.07%	94
2017 Q2	$303K	Buy	3,998 +183	+5%	+$12.8K	0.05%	102
2017 Q1	$252K	Buy	3,815 +457	+14%	+$30.1K	0.05%	105
2016 Q4	$213K	Buy	+3,358	New	+$212K	0.04%	109

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Campbell Newman Asset Management's LGND Position: Q1 2019 in Review

Campbell Newman Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 6,547 shares — an estimated $554K sold.

Campbell Newman Asset Management first reported a position in LGND in Q4 2016 and held it in 9 quarters. The position peaked at $791K in Q2 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

Campbell Newman Asset Management reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Campbell Newman Asset Management sold 6,547 Ligand Pharmaceuticals shares in Q1 2019, an estimated $554K.
Campbell Newman Asset Management first reported a position in Ligand Pharmaceuticals in Q4 2016 and held it in 9 quarters.
Campbell Newman Asset Management's Ligand Pharmaceuticals position peaked at $791K in Q2 2018.
330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Campbell Newman Asset Management's 13F filing for Q1 2019, filed 9 Apr 2019.